JPMorgan Chase & Co. Issues Positive Forecast for Smith & Nephew (LON:SN) Stock Price

Key Points

• JPMorgan Chase & Co. has raised the price target for Smith & Nephew from GBX 1,357 to GBX 1,438, suggesting an upside potential of 8.04% from its current stock price.
• Smith & Nephew's stock has seen a significant increase, climbing 15.3% to open at GBX 1,331.
• The company has a market capitalization of £14.59 billion and operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.

Smith & Nephew (LON:SN - Get Free Report) had its price target boosted by analysts at JPMorgan Chase & Co. from GBX 1,357 ($18.25) to GBX 1,438 ($19.34) in a research report issued to clients and investors on Wednesday, MarketBeat Ratings reports. The brokerage currently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s target price points to a potential upside of 6.95% from the stock's previous close.

Smith & Nephew Trading Up 0.5%

LON SN traded up GBX 7 ($0.09) on Wednesday, hitting GBX 1,344.50 ($18.08). 2,958,968 shares of the company were exchanged, compared to its average volume of 343,671. The firm's fifty day simple moving average is GBX 1,129.06 and its 200 day simple moving average is GBX 1,079.76. The company has a market cap of £14.74 billion, a P/E ratio of 48.41, a P/E/G ratio of 0.46 and a beta of 0.62. The company has a current ratio of 2.51, a quick ratio of 0.84 and a debt-to-equity ratio of 70.22.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.